Drug Trial Radar · NCT06818058
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 20, 2025
Primary completion
Sep 1, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Tarian PharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.
Conditions
- EGFR Inhibitor-associated Rash
Interventions
Brimonidine tartrate GelDrug
Once daily applications for 7 days
Placebo gel (no Brimonidine tartrate)Drug
Once daily applications for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment - emergent Advers Events (TEAEs)Time frame: At Baseline and then at Day 14, Day 28, Day 42 and Day 56 .
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hopital Privé Jean Mermoz
Lyon, France · Recruiting
Institut Paoli Calmette
Marseille, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.